United Therapeutics Corporation

The quality-price interaction here is unusual: you're getting a near-monopoly rare disease franchise with genuinely exceptional returns on capital, clean cash conversion, and a founder-operator who has earned the right to be trusted with speculative capital — all at a multiple that implies the growth story is essentially over. That's the mispricing. The business generates enough free cash to self-fund both aggressive buybacks and a generational infrastructure bet simultaneously, which is a combination you almost never see. The trajectory is a layered option stack. The base case — treprostinil extensions into IPF and eventually PH-COPD — expands the addressable patient population by multiples without requiring new chemistry. Ralinepag, if the outcomes data holds, introduces a new mechanism that could grow the total PAH market rather than just taking share. And running beneath all of it, xenotransplantation is either the most important medical infrastructure investment of this decade or an enormously expensive science project — but the clinical milestones are advancing, and a credible FDA pathway would reprice the entire enterprise. The single biggest risk is not competitive — it's political. This business is a nearly pure expression of the US orphan drug pricing ecosystem, where payers lack leverage and physicians lack alternatives. Any meaningful structural reform to that pricing regime — drug negotiation expanded to orphan indications, mandatory rebate floors, reference pricing — would hit the revenue model directly and without warning. The international revenue is too small to cushion the blow. Washington is the risk that no amount of scientific genius or delivery-route innovation can hedge.